Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic
Parkinson's disease (PD). However, strategies aimed at ameliorating mitochondrial …

Abstract Development of novel therapies for central nervous system (CNS) disorders has
experienced a high failure rate in clinical trials owing to unsatisfactory efficacy and adverse …

A key hallmark of Parkinson's disease (PD) is Lewy pathology. Composed of α-synuclein,
Lewy pathology is found both in dopaminergic neurons that modulate motor function, and …

In Parkinson disease (PD), pathological processes and neurodegeneration begin long
before the cardinal motor symptoms develop and enable clinical diagnosis. In this prodromal …

The concept of 'idiopathic'Parkinson's disease (PD) as a single entity has been challenged
with the identification of several clinical subtypes, pathogenic genes and putative causative …

Parkinson's disease (PD) is characterized pathologically by the loss of dopaminergic (DA)
neurons in the substantia nigra (SN). Whether cell types beyond DA neurons in the SN show …

That certain cell types in the central nervous system are more likely to undergo
neurodegeneration in Parkinson's disease is a widely appreciated but poorly understood …

Parkinson's disease (PD) is a common neurodegenerative disorder. While a number of
nonmotor manifestations arise, the typical clinical features involve a movement disorder …

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by
motor and non-motor symptoms. More than 200 years after its first clinical description, PD …

A new model of Parkinson's disease (PD) pathogenesis is proposed, the α-Synuclein Origin
site and Connectome (SOC) model, incorporating two aspects of α-synuclein pathobiology …